93 related articles for article (PubMed ID: 22837469)
1. Immunization with a combination of 2 peptides derived from the C5a receptor significantly reduces early atherosclerotic lesion in Ldlr(tm1Her) Apob(tm2Sgy) J mice.
Lu X; Xia M; Endresz V; Faludi I; Mundkur L; Gonczol E; Chen D; Kakkar VV
Arterioscler Thromb Vasc Biol; 2012 Oct; 32(10):2358-71. PubMed ID: 22837469
[TBL] [Abstract][Full Text] [Related]
2. Impact of multiple antigenic epitopes from ApoB100, hHSP60 and Chlamydophila pneumoniae on atherosclerotic lesion development in Apob(tm2Sgy)Ldlr(tm1Her)J mice.
Lu X; Xia M; Endresz V; Faludi I; Szabo A; Gonczol E; Mundkur L; Chen D; Kakkar V
Atherosclerosis; 2012 Nov; 225(1):56-68. PubMed ID: 22959702
[TBL] [Abstract][Full Text] [Related]
3. Immunization of Chlamydia pneumoniae (Cpn)-infected Apob(tm2Sgy)Ldlr(tm1Her)/J mice with a combined peptide of Cpn significantly reduces atherosclerotic lesion development.
Xia M; Chen D; Endresz V; Faludi I; Szabo A; Gonczol E; Kakkar V; Lu X
PLoS One; 2013; 8(12):e81056. PubMed ID: 24349031
[TBL] [Abstract][Full Text] [Related]
4. C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice.
Shagdarsuren E; Bidzhekov K; Mause SF; Simsekyilmaz S; Polakowski T; Hawlisch H; Gessner JE; Zernecke A; Weber C
Circulation; 2010 Sep; 122(10):1026-36. PubMed ID: 20733098
[TBL] [Abstract][Full Text] [Related]
5. Immunization with a combination of ApoB and HSP60 epitopes significantly reduces early atherosclerotic lesion in Apobtm2SgyLdlrtm1Her/J mice.
Lu X; Chen D; Endresz V; Xia M; Faludi I; Burian K; Szabo A; Csanadi A; Miczak A; Gonczol E; Kakkar V
Atherosclerosis; 2010 Oct; 212(2):472-80. PubMed ID: 20609438
[TBL] [Abstract][Full Text] [Related]
6. Modulation of recombinant antigenic constructs containing multi-epitopes towards effective reduction of atherosclerotic lesion in B6;129S-Ldlr(tm1Her)Apob(tm2Sgy)/J mice.
Xia M; Chen D; Endresz V; Lantos I; Szabo A; Kakkar V; Lu X
PLoS One; 2015; 10(4):e0123393. PubMed ID: 25830298
[TBL] [Abstract][Full Text] [Related]
7. Mucosal tolerance to a combination of ApoB and HSP60 peptides controls plaque progression and stabilizes vulnerable plaque in Apob(tm2Sgy)Ldlr(tm1Her)/J mice.
Mundkur L; Mukhopadhyay R; Samson S; Varma M; Kale D; Chen D; Shivaprasad S; Sivanandan H; Soman V; Lu X; Kakkar VV
PLoS One; 2013; 8(3):e58364. PubMed ID: 23505495
[TBL] [Abstract][Full Text] [Related]
8. Immune regulation by oral tolerance induces alternate activation of macrophages and reduces markers of plaque destabilization in Apob
Thota LN; Ponnusamy T; Philip S; Lu X; Mundkur L
Sci Rep; 2017 Jun; 7(1):3997. PubMed ID: 28638138
[TBL] [Abstract][Full Text] [Related]
9. Hypercholesterolemia Induced Immune Response and Inflammation on Progression of Atherosclerosis in Apob(tm2Sgy) Ldlr(tm1Her)/J Mice.
Rao LN; Ponnusamy T; Philip S; Mukhopadhyay R; Kakkar VV; Mundkur L
Lipids; 2015 Aug; 50(8):785-97. PubMed ID: 26178198
[TBL] [Abstract][Full Text] [Related]
10. Immunization of apoE-/- mice with aldehyde-modified fibronectin inhibits the development of atherosclerosis.
Dunér P; To F; Beckmann K; Björkbacka H; Fredrikson GN; Nilsson J; Bengtsson E
Cardiovasc Res; 2011 Aug; 91(3):528-36. PubMed ID: 21493703
[TBL] [Abstract][Full Text] [Related]
11. Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice.
Manthey HD; Thomas AC; Shiels IA; Zernecke A; Woodruff TM; Rolfe B; Taylor SM
FASEB J; 2011 Jul; 25(7):2447-55. PubMed ID: 21490292
[TBL] [Abstract][Full Text] [Related]
12. Activation of inflammatory cells and cytokines by peptide epitopes in vitro: a simple in-vitro screening assay for prioritizing them for in-vivo studies.
Mundkur LA; Varma M; Shivanandan H; Krishna D; Kumar K; Lu X; Kakkar VV
Inflamm Res; 2013 May; 62(5):471-81. PubMed ID: 23400302
[TBL] [Abstract][Full Text] [Related]
13. Egr-1 deficiency in bone marrow-derived cells reduces atherosclerotic lesion formation in a hyperlipidaemic mouse model.
Albrecht C; Preusch MR; Hofmann G; Morris-Rosenfeld S; Blessing E; Rosenfeld ME; Katus HA; Bea F
Cardiovasc Res; 2010 May; 86(2):321-9. PubMed ID: 20110335
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow-specific deficiency of nuclear receptor Nur77 enhances atherosclerosis.
Hamers AA; Vos M; Rassam F; Marinković G; Kurakula K; van Gorp PJ; de Winther MP; Gijbels MJ; de Waard V; de Vries CJ
Circ Res; 2012 Feb; 110(3):428-38. PubMed ID: 22194623
[TBL] [Abstract][Full Text] [Related]
15. C5a/C5aR pathway is essential for the pathogenesis of murine viral fulminant hepatitis by way of potentiating Fgl2/fibroleukin expression.
Xu GL; Chen J; Yang F; Li GQ; Zheng LX; Wu YZ
Hepatology; 2014 Jul; 60(1):114-24. PubMed ID: 24604562
[TBL] [Abstract][Full Text] [Related]
16. Probing the human receptor for C5a anaphylatoxin with site-directed antibodies. Identification of a potential ligand binding site on the NH2-terminal domain.
Oppermann M; Raedt U; Hebell T; Schmidt B; Zimmermann B; Götze O
J Immunol; 1993 Oct; 151(7):3785-94. PubMed ID: 8376805
[TBL] [Abstract][Full Text] [Related]
17. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
Babaev VR; Ishiguro H; Ding L; Yancey PG; Dove DE; Kovacs WJ; Semenkovich CF; Fazio S; Linton MF
Circulation; 2007 Sep; 116(12):1404-12. PubMed ID: 17724261
[TBL] [Abstract][Full Text] [Related]
18. Role of C5a-C5aR axis in the development of atherosclerosis.
An G; Ren G; An F; Zhang C
Sci China Life Sci; 2014 Aug; 57(8):790-4. PubMed ID: 25104451
[TBL] [Abstract][Full Text] [Related]
19. High expression of C5L2 correlates with high proinflammatory cytokine expression in advanced human atherosclerotic plaques.
Vijayan S; Asare Y; Grommes J; Soehnlein O; Lutgens E; Shagdarsuren G; Togtokh A; Jacobs MJ; Fischer JW; Bernhagen J; Weber C; Schober A; Shagdarsuren E
Am J Pathol; 2014 Jul; 184(7):2123-33. PubMed ID: 24819959
[TBL] [Abstract][Full Text] [Related]
20. C5a and bradykinin receptor cross-talk regulates innate and adaptive immunity in Trypanosoma cruzi infection.
Schmitz V; Almeida LN; Svensjö E; Monteiro AC; Köhl J; Scharfstein J
J Immunol; 2014 Oct; 193(7):3613-23. PubMed ID: 25187655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
